[go: up one dir, main page]

EA201992688A1 - Средства, пути применения и способы лечения - Google Patents

Средства, пути применения и способы лечения

Info

Publication number
EA201992688A1
EA201992688A1 EA201992688A EA201992688A EA201992688A1 EA 201992688 A1 EA201992688 A1 EA 201992688A1 EA 201992688 A EA201992688 A EA 201992688A EA 201992688 A EA201992688 A EA 201992688A EA 201992688 A1 EA201992688 A1 EA 201992688A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
ways
methods
application
antibodies
Prior art date
Application number
EA201992688A
Other languages
English (en)
Inventor
Ларс Кристиан Биилманн Ронн
Ибрагим Джон Малик
Джеффри Б. Ставенхаген
Сёрен Кристенен
Ян Эгебьйерг
Тина Стумманн
Арноут Герритсен
Эдвард Ван Ден Бринк
Пол Паррен
Эсбен Трабьйерг
Каспер Дайберг Ранд
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201992688A1 publication Critical patent/EA201992688A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к моноклональным антителам к сортилину, которые, как было обнаружено, являются применимыми при коррекции дефицитного уровня програнулина (PGRN). В частности, эти антитела можно применять в лечении лобно-височной деменции (FTD) и бокового амиотрофического склероза (ALS), и других нейродегенеративных заболеваний, таких как болезнь Альцгеймера (AD).
EA201992688A 2017-07-20 2018-07-18 Средства, пути применения и способы лечения EA201992688A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20
PCT/EP2018/069460 WO2019016247A2 (en) 2017-07-20 2018-07-18 AGENTS, USES AND METHODS OF TREATMENT

Publications (1)

Publication Number Publication Date
EA201992688A1 true EA201992688A1 (ru) 2020-05-20

Family

ID=63113476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992688A EA201992688A1 (ru) 2017-07-20 2018-07-18 Средства, пути применения и способы лечения

Country Status (25)

Country Link
US (2) US10894833B2 (ru)
EP (1) EP3655438A2 (ru)
JP (2) JP7563975B2 (ru)
KR (1) KR102800556B1 (ru)
CN (3) CN110945029B (ru)
AR (1) AR112563A1 (ru)
AU (1) AU2018303175B2 (ru)
BR (1) BR112019005428A2 (ru)
CA (1) CA3069391A1 (ru)
CL (1) CL2020000070A1 (ru)
CO (1) CO2019014090A2 (ru)
CR (1) CR20200027A (ru)
DO (1) DOP2020000006A (ru)
EA (1) EA201992688A1 (ru)
EC (1) ECSP20002935A (ru)
IL (1) IL271728B2 (ru)
JO (1) JOP20200007A1 (ru)
MA (1) MA49633A (ru)
NI (1) NI202000005A (ru)
PE (1) PE20210467A1 (ru)
PH (1) PH12019502869A1 (ru)
RU (1) RU2019140933A (ru)
SG (1) SG11201912228WA (ru)
TW (1) TW201908342A (ru)
WO (1) WO2019016247A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2019246837B2 (en) 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof
AU2020217012A1 (en) * 2019-02-01 2021-08-19 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
BR112021025077A2 (pt) * 2019-06-11 2022-05-03 Alector Llc Anticorpos anti-sortilina para uso em terapia
EP4171743A4 (en) * 2020-06-24 2024-07-24 Prothena Biosciences Limited Antibodies recognizing sortilin
EP4543858A1 (en) 2022-06-23 2025-04-30 Draupnir Bio ApS Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1589988A2 (en) 2002-12-20 2005-11-02 Neuronicon ApS Modulation of activity of neurotrophins
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
HUE031611T2 (en) 2006-12-21 2017-07-28 H Lundbeck As Modulation of Pronurotrophin Activity
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
EP2249861B1 (en) * 2008-01-16 2016-07-06 Neurodyn Life Sciences Inc. Progranulin for use in treating parkinson's disease or alzheimer's disease
EP2274327B1 (en) 2008-04-27 2019-03-27 H. Lundbeck A/S Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US8703125B2 (en) 2008-12-19 2014-04-22 H. Lundbeck A/S Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
US10149836B2 (en) * 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
CA2942713A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EA201792221A1 (ru) * 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2018185232A1 (en) * 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
AU2019246837B2 (en) * 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Also Published As

Publication number Publication date
RU2019140933A3 (ru) 2021-10-28
TW201908342A (zh) 2019-03-01
KR20200031610A (ko) 2020-03-24
AU2018303175B2 (en) 2025-01-23
WO2019016247A2 (en) 2019-01-24
CO2019014090A2 (es) 2020-01-17
BR112019005428A2 (pt) 2019-07-16
US20190023788A1 (en) 2019-01-24
AR112563A1 (es) 2019-11-13
RU2019140933A (ru) 2021-08-20
NI202000005A (es) 2020-05-20
CN119161481A (zh) 2024-12-20
CN119161480A (zh) 2024-12-20
US10894833B2 (en) 2021-01-19
JOP20200007A1 (ar) 2020-01-15
JP7563975B2 (ja) 2024-10-08
US20210292414A1 (en) 2021-09-23
PH12019502869A1 (en) 2020-09-28
JP2020527152A (ja) 2020-09-03
CA3069391A1 (en) 2019-01-24
MA49633A (fr) 2020-05-27
KR102800556B1 (ko) 2025-04-24
SG11201912228WA (en) 2020-01-30
CN110945029A (zh) 2020-03-31
AU2018303175A1 (en) 2020-01-16
PE20210467A1 (es) 2021-03-08
EP3655438A2 (en) 2020-05-27
IL271728B1 (en) 2024-01-01
CN110945029B (zh) 2024-10-01
CR20200027A (es) 2020-04-17
JP2024119866A (ja) 2024-09-03
ECSP20002935A (es) 2020-02-28
CL2020000070A1 (es) 2020-06-12
IL271728B2 (en) 2024-05-01
IL271728A (en) 2020-02-27
WO2019016247A3 (en) 2019-06-20
DOP2020000006A (es) 2020-07-15

Similar Documents

Publication Publication Date Title
EA201992688A1 (ru) Средства, пути применения и способы лечения
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201791590A1 (ru) Антитела к tau и их применение
JOP20190247A1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201990400A1 (ru) Соединения и композиции и их применение
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
GEP20247700B (en) Antibody variants
MA42270B1 (fr) Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38